Epicutaneous Immunotherapy: A Novel Pathway in Development for the Treatment of Food Allergies
Sunday, March 6, 2016: 6:30 PM-8:30 PM
JW Marriott, Diamond Ballroom Level, Salon 4
0.00 CME/CE
This program is not sponsored or programmed by the AAAAI.

Sponsored by DBV Technologies.

Presenters:

Pierre-Henri Benhamou, MD, CEO of DBV Technologies

Drew Bird, MD

Kari Nadeau, MD, PhD

Jonathan Spergel, MD, PhD

Hugh Sampson, MD, CSO of DBV Technologies & Director of the Jaffe Food Allergy Institute at the Icahn School of Medicine at Mount Sinai (Moderator)

Epicutaneous immunotherapy (EPIT) is an innovative treatment approach for food-allergic patients. Clinical trial data support treatment efficacy, favorable safety profile, and strong patient compliance. This symposium will explore the scientific foundations, body of clinical evidence, and potential implications for food- and pediatric-allergic patients. Emerging data in peanut and milk allergy will be presented as well as its broader application in the field of food allergy, including eosinophilic esophagitis. This new class of self-administered and non-invasive products candidates is dedicated to safely transforming the care of food-allergic patients.

Dinner will be provided.